array(40) {
  [0]=>
  string(4) "1986"
  ["article_id"]=>
  string(4) "1986"
  [1]=>
  string(133) "FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need"
  ["article_title"]=>
  string(133) "FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need"
  [2]=>
  string(150) "VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn” or the “Company”), a late stage biotechnology"
  ["short_description"]=>
  string(150) "VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn” or the “Company”), a late stage biotechnology"
  [3]=>
  string(244) "VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple..."
  ["description"]=>
  string(244) "VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc., (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/fda-grants-cytodyn-fast-track-designation-leronlimab-pro-140-metastatic-triple-negative-breast-18133.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Grants+CytoDyn+Fast+Track+Designation+for+Leronlimab+%28PRO+140%29+in+metastatic+Triple-Negative+Breast+Cance"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/fda-grants-cytodyn-fast-track-designation-leronlimab-pro-140-metastatic-triple-negative-breast-18133.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Grants+CytoDyn+Fast+Track+Designation+for+Leronlimab+%28PRO+140%29+in+metastatic+Triple-Negative+Breast+Cance"
  [15]=>
  string(19) "2019-05-07 14:05:30"
  ["add_date"]=>
  string(19) "2019-05-07 14:05:30"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2080"
  ["article_id"]=>
  string(4) "2080"
  [1]=>
  string(37) "Merging cell datasets, panorama style"
  ["article_title"]=>
  string(37) "Merging cell datasets, panorama style"
  [2]=>
  string(150) "A new algorithm takes cues from panoramic photography to merge massive, diverse cell datasets into a single source that can be used for medical and bi"
  ["short_description"]=>
  string(150) "A new algorithm takes cues from panoramic photography to merge massive, diverse cell datasets into a single source that can be used for medical and bi"
  [3]=>
  string(168) "A new algorithm takes cues from panoramic photography to merge massive, diverse cell datasets into a single source that can be used for medical and biological studies. "
  ["description"]=>
  string(168) "A new algorithm takes cues from panoramic photography to merge massive, diverse cell datasets into a single source that can be used for medical and biological studies. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190506190106.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190506190106.htm"
  [15]=>
  string(19) "2019-05-07 07:01:06"
  ["add_date"]=>
  string(19) "2019-05-07 07:01:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2024"
  ["article_id"]=>
  string(4) "2024"
  [1]=>
  string(47) "Amgen Takes Sensipar Dispute to Appellate Court"
  ["article_title"]=>
  string(47) "Amgen Takes Sensipar Dispute to Appellate Court"
  [2]=>
  string(158) "&#nl        A dispute between Amgen and generics maker Cipla is headed to appellate court after a federal judge turned aside Amgen’s effort to get Cipl"
  ["short_description"]=>
  string(158) "&#nl        A dispute between Amgen and generics maker Cipla is headed to appellate court after a federal judge turned aside Amgen’s effort to get Cipl"
  [3]=>
  string(267) "&#nl        A dispute between Amgen and generics maker Cipla is headed to appellate court after a federal judge turned aside Amgen’s effort to get Cipla to stop making generics of the blockbuster Sensipar while the two companies litigate over rights.&#nl      "
  ["description"]=>
  string(267) "&#nl        A dispute between Amgen and generics maker Cipla is headed to appellate court after a federal judge turned aside Amgen’s effort to get Cipla to stop making generics of the blockbuster Sensipar while the two companies litigate over rights.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(87) "https://www.fdanews.com/articles/191203-amgen-takes-sensipar-dispute-to-appellate-court"
  ["blog_url"]=>
  string(87) "https://www.fdanews.com/articles/191203-amgen-takes-sensipar-dispute-to-appellate-court"
  [15]=>
  string(19) "2019-05-07 05:41:11"
  ["add_date"]=>
  string(19) "2019-05-07 05:41:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2025"
  ["article_id"]=>
  string(4) "2025"
  [1]=>
  string(72) "GlaxoSmithKline Slammed With $90 Million Verdict for Patent Infringement"
  ["article_title"]=>
  string(72) "GlaxoSmithKline Slammed With $90 Million Verdict for Patent Infringement"
  [2]=>
  string(158) "&#nl        Pharma giant GlaxoSmithKline infringed upon UK-based Vectura’s patent on particle manufacturing and must pay the company $89.7 million, a f"
  ["short_description"]=>
  string(158) "&#nl        Pharma giant GlaxoSmithKline infringed upon UK-based Vectura’s patent on particle manufacturing and must pay the company $89.7 million, a f"
  [3]=>
  string(198) "&#nl        Pharma giant GlaxoSmithKline infringed upon UK-based Vectura’s patent on particle manufacturing and must pay the company $89.7 million, a federal jury in Delaware ruled.&#nl      "
  ["description"]=>
  string(198) "&#nl        Pharma giant GlaxoSmithKline infringed upon UK-based Vectura’s patent on particle manufacturing and must pay the company $89.7 million, a federal jury in Delaware ruled.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(111) "https://www.fdanews.com/articles/191201-glaxosmithkline-slammed-with-90-million-verdict-for-patent-infringement"
  ["blog_url"]=>
  string(111) "https://www.fdanews.com/articles/191201-glaxosmithkline-slammed-with-90-million-verdict-for-patent-infringement"
  [15]=>
  string(19) "2019-05-07 05:39:41"
  ["add_date"]=>
  string(19) "2019-05-07 05:39:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1981"
  ["article_id"]=>
  string(4) "1981"
  [1]=>
  string(43) "EMA Reviews Two Decades of Drug Inspections"
  ["article_title"]=>
  string(43) "EMA Reviews Two Decades of Drug Inspections"
  [2]=>
  string(153) "&#nl        EU regulators flagged 18 percent of inspected biologics and nine percent of inspected drugs for scientific or regulatory problems in the two "
  ["short_description"]=>
  string(153) "&#nl        EU regulators flagged 18 percent of inspected biologics and nine percent of inspected drugs for scientific or regulatory problems in the two "
  [3]=>
  string(287) "&#nl        EU regulators flagged 18 percent of inspected biologics and nine percent of inspected drugs for scientific or regulatory problems in the two decades since European regulators began inspecting drugs and medicines, the European Medicines Agency said in a new report. &#nl      "
  ["description"]=>
  string(287) "&#nl        EU regulators flagged 18 percent of inspected biologics and nine percent of inspected drugs for scientific or regulatory problems in the two decades since European regulators began inspecting drugs and medicines, the European Medicines Agency said in a new report. &#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "14"
  ["rss_id"]=>
  string(2) "14"
  [14]=>
  string(83) "https://www.fdanews.com/articles/191198-ema-reviews-two-decades-of-drug-inspections"
  ["blog_url"]=>
  string(83) "https://www.fdanews.com/articles/191198-ema-reviews-two-decades-of-drug-inspections"
  [15]=>
  string(19) "2019-05-07 05:22:45"
  ["add_date"]=>
  string(19) "2019-05-07 05:22:45"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:56"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:56"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1982"
  ["article_id"]=>
  string(4) "1982"
  [1]=>
  string(73) "FDA Urged to Clarify Voluntary Quality Standards for Combination Products"
  ["article_title"]=>
  string(73) "FDA Urged to Clarify Voluntary Quality Standards for Combination Products"
  [2]=>
  string(158) "&#nl        A trade group representing combination drug products is urging the FDA to draw bright lines among the agency’s centers as it considers volu"
  ["short_description"]=>
  string(158) "&#nl        A trade group representing combination drug products is urging the FDA to draw bright lines among the agency’s centers as it considers volu"
  [3]=>
  string(192) "&#nl        A trade group representing combination drug products is urging the FDA to draw bright lines among the agency’s centers as it considers voluntary quality standards.&#nl      "
  ["description"]=>
  string(192) "&#nl        A trade group representing combination drug products is urging the FDA to draw bright lines among the agency’s centers as it considers voluntary quality standards.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "14"
  ["rss_id"]=>
  string(2) "14"
  [14]=>
  string(113) "https://www.fdanews.com/articles/191193-fda-urged-to-clarify-voluntary-quality-standards-for-combination-products"
  ["blog_url"]=>
  string(113) "https://www.fdanews.com/articles/191193-fda-urged-to-clarify-voluntary-quality-standards-for-combination-products"
  [15]=>
  string(19) "2019-05-07 05:20:32"
  ["add_date"]=>
  string(19) "2019-05-07 05:20:32"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:56"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:56"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2144"
  ["article_id"]=>
  string(4) "2144"
  [1]=>
  string(67) "Boston Scientific Launches New Stent for Venous Obstructive Disease"
  ["article_title"]=>
  string(67) "Boston Scientific Launches New Stent for Venous Obstructive Disease"
  [2]=>
  string(156) "&#nlBoston Scientific has won FDA approval for its Vici Venous Stent System for the treatment of iliofemoral venous obstructive disease.&#nlThe deviceÂ"
  ["short_description"]=>
  string(156) "&#nlBoston Scientific has won FDA approval for its Vici Venous Stent System for the treatment of iliofemoral venous obstructive disease.&#nlThe deviceÂ"
  [3]=>
  string(2656) "&#nl
Boston Scientific has won FDA approval for its Vici Venous Stent System for the treatment of iliofemoral venous obstructive disease.
&#nl
The device received CE mark in 2013, and was developed by Veniti, one of the many companies Boston Scientific acquired last year. The company paid $108 million for Veniti last August, and FDA approval of the Vici Stent System satisfies one of the milestones for up to another $52 million.
&#nl
Iliofemoral venous obstructive disease occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies. Endovascular treatment for venous obstructive disease is focused on restoring the normal flow of blood from the legs back to the heart. Because the iliofemoral veins are located deep in the pelvis, they may be subject to significant crushing forces from other anatomical structures such as the right common iliac artery. To help solve for this, the Vici stent system was designed to be uniformly strong and crush resistant, capable of restoring blood blow by creating a cylindrical, patent vessel.
&#nl
FDA approval was supported by data from the VIRTUS study, a prospective, multi-center, single-arm study with 170 patients. The VIRTUS study evaluated the stent in relation to pre-defined objective performance goals in patients with a clinically significant obstruction in the illiofemoral venous outflow tract. It met its primary safety and effectiveness endpoints.
&#nl
According to Mahmood Razavi, MD, at Orange, CA-based St. Joseph Hospital, venous obstructive disease can cause quality of life issues without optimized treatment options.
&#nl
"With the approval of the Vici stent, clinicians now have access to a stent that was purposely developed and engineered to resist the vessel compression and anatomical tortuosity commonly found within the iliofemoral venous system, enabling our ability to deliver best outcomes for our patients,” Razavi said.
&#nl
Boston Scientific noted that venous obstructive disease affects nearly 40% of the U.S. population and can be caused by conditions such as deep vein thrombosis, post-thrombotic syndrome, and compressive diseases such as May-Thurner syndrome. In patients with venous obstructions, blood may pool in the legs, resulting in pain, swelling, and skin ulcers.
"
  ["description"]=>
  string(2656) "&#nl
Boston Scientific has won FDA approval for its Vici Venous Stent System for the treatment of iliofemoral venous obstructive disease.
&#nl
The device received CE mark in 2013, and was developed by Veniti, one of the many companies Boston Scientific acquired last year. The company paid $108 million for Veniti last August, and FDA approval of the Vici Stent System satisfies one of the milestones for up to another $52 million.
&#nl
Iliofemoral venous obstructive disease occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked by a blood clot or compressed by anatomical anomalies. Endovascular treatment for venous obstructive disease is focused on restoring the normal flow of blood from the legs back to the heart. Because the iliofemoral veins are located deep in the pelvis, they may be subject to significant crushing forces from other anatomical structures such as the right common iliac artery. To help solve for this, the Vici stent system was designed to be uniformly strong and crush resistant, capable of restoring blood blow by creating a cylindrical, patent vessel.
&#nl
FDA approval was supported by data from the VIRTUS study, a prospective, multi-center, single-arm study with 170 patients. The VIRTUS study evaluated the stent in relation to pre-defined objective performance goals in patients with a clinically significant obstruction in the illiofemoral venous outflow tract. It met its primary safety and effectiveness endpoints.
&#nl
According to Mahmood Razavi, MD, at Orange, CA-based St. Joseph Hospital, venous obstructive disease can cause quality of life issues without optimized treatment options.
&#nl
"With the approval of the Vici stent, clinicians now have access to a stent that was purposely developed and engineered to resist the vessel compression and anatomical tortuosity commonly found within the iliofemoral venous system, enabling our ability to deliver best outcomes for our patients,” Razavi said.
&#nl
Boston Scientific noted that venous obstructive disease affects nearly 40% of the U.S. population and can be caused by conditions such as deep vein thrombosis, post-thrombotic syndrome, and compressive diseases such as May-Thurner syndrome. In patients with venous obstructions, blood may pool in the legs, resulting in pain, swelling, and skin ulcers.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(90) "https://www.mddionline.com/boston-scientific-launches-new-stent-venous-obstructive-disease"
  ["blog_url"]=>
  string(90) "https://www.mddionline.com/boston-scientific-launches-new-stent-venous-obstructive-disease"
  [15]=>
  string(19) "2019-05-07 04:43:12"
  ["add_date"]=>
  string(19) "2019-05-07 04:43:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:39"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2081"
  ["article_id"]=>
  string(4) "2081"
  [1]=>
  string(92) "Transplanting gut bacteria alters depression-related behavior, brain inflammation in animals"
  ["article_title"]=>
  string(92) "Transplanting gut bacteria alters depression-related behavior, brain inflammation in animals"
  [2]=>
  string(150) "Scientists have shown that transplanting gut bacteria, from an animal that is vulnerable to social stress to a non-stressed animal, can cause vulnerab"
  ["short_description"]=>
  string(150) "Scientists have shown that transplanting gut bacteria, from an animal that is vulnerable to social stress to a non-stressed animal, can cause vulnerab"
  [3]=>
  string(360) "Scientists have shown that transplanting gut bacteria, from an animal that is vulnerable to social stress to a non-stressed animal, can cause vulnerable behavior in the recipient. The research reveals details of biological interactions between the brain and gut that may someday lead to probiotic treatments for human psychiatric disorders such as depression. "
  ["description"]=>
  string(360) "Scientists have shown that transplanting gut bacteria, from an animal that is vulnerable to social stress to a non-stressed animal, can cause vulnerable behavior in the recipient. The research reveals details of biological interactions between the brain and gut that may someday lead to probiotic treatments for human psychiatric disorders such as depression. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190506163642.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190506163642.htm"
  [15]=>
  string(19) "2019-05-07 04:36:42"
  ["add_date"]=>
  string(19) "2019-05-07 04:36:42"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2051"
  ["article_id"]=>
  string(4) "2051"
  [1]=>
  string(70) "Amedisys Celebrates More Than 7,000 Nurses During National Nurses Week"
  ["article_title"]=>
  string(70) "Amedisys Celebrates More Than 7,000 Nurses During National Nurses Week"
  [2]=>
  string(155) "BATON ROUGE, La., May  06, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home healthcare, hospice and personal"
  ["short_description"]=>
  string(155) "BATON ROUGE, La., May  06, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home healthcare, hospice and personal"
  [3]=>
  string(297) "
BATON ROUGE, La., May  06, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home healthcare, hospice and personal care companies, celebrates National Nurses Week by honoring more than 7,000 nurses who call the company home.
"
  ["description"]=>
  string(297) "
BATON ROUGE, La., May  06, 2019  (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home healthcare, hospice and personal care companies, celebrates National Nurses Week by honoring more than 7,000 nurses who call the company home.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(141) "http://www.globenewswire.com/news-release/2019/05/06/1817874/0/en/Amedisys-Celebrates-More-Than-7-000-Nurses-During-National-Nurses-Week.html"
  ["blog_url"]=>
  string(141) "http://www.globenewswire.com/news-release/2019/05/06/1817874/0/en/Amedisys-Celebrates-More-Than-7-000-Nurses-During-National-Nurses-Week.html"
  [15]=>
  string(19) "2019-05-07 04:30:00"
  ["add_date"]=>
  string(19) "2019-05-07 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:16"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:16"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2145"
  ["article_id"]=>
  string(4) "2145"
  [1]=>
  string(72) "How Endologix Renewed One Doctor's Confidence in the Ovation Device"
  ["article_title"]=>
  string(72) "How Endologix Renewed One Doctor's Confidence in the Ovation Device"
  [2]=>
  string(160) "&#nlIt's been a turbulent couple of years for Endologix, but as MD+DI reported in February, the company has been working hard to win back customers.&#nlDuri"
  ["short_description"]=>
  string(160) "&#nlIt's been a turbulent couple of years for Endologix, but as MD+DI reported in February, the company has been working hard to win back customers.&#nlDuri"
  [3]=>
  string(5083) "&#nl
It's been a turbulent couple of years for Endologix, but as MD+DI reported in February, the company has been working hard to win back customers.
&#nl
During the company's first-quarter earnings call, CEO John Onopchenko shared a story about a physician at an academic medical center in the Western United States (he did not disclose the name of the physician or the center) who had used Ovation only twice over the course of 2017 and 2018. 
&#nl
Irvine, CA-based Endologix acquired the Ovation platform through its merger with TriVascular in February 2016. It's a low-profile device that has broadened the company's portfolio in terms of patients that can be treated. In June 2017, Endologix reported positive 30-day results from a study evaluating EVAR in women using the Ovation system.
&#nl
"His reasons for not using it more frequently were that there were limited data available and he believed it to be a technically challenging product to deploy," Onopchenko said. "And frankly, he chose as those initial cases, really a challenging reverse-tapered-neck presentation."
&#nl
Late last year, Endologix initiated multiple conversations with this doctor to explain the "why" behind the design of Ovation, along with new evidence in the form of five-year ENCORE data, and those conversations intrigued the doctor enough to spend a day visiting the company's Santa Rosa, CA facility in late January to meet with Onopchenko and other company reps.
&#nl
"He gained a better understanding of the evidence, and he also saw the manufacturing process where Ovation is created first hand," Onopchenko said. "And I’ve got to tell you – I’ve now witnessed this several times – when physicians see how the device is created, it is quite a remarkable experience. Additionally, while we were in Santa Rosa, he completed a successful simulated Ovation device deployment, which is a huge step in uncovering why he initially believed it was technically challenging."
&#nl
Onopchenko said being able to purposefully explain to physicians "the why" behind each step in the process of deploying the endograft goes a long way toward changing how the Ovation device is perceived.
&#nl
"It demystifies and it greatly reduces the initial reaction that our competitors' fuel about it being a technically challenging procedure," Onopchenko said.
&#nl
The visit also allowed that particular physician an opportunity to better identify appropriate Ovation patient selection. The doctor has now treated five patients with Ovation in just the last 60 days, Onopchenko said, and he is now an active site for the company's EVAS2 trial.
&#nl
Here are the reasons the physician gave Endologix for why he has begun to integrate Ovation into his practice since the facility visit.
&#nl
1. The Ability to Treat More Patients on IFU
&#nl
Onopchenko said the doctor is able to treat more patients in accordance with the product label's instructions for use, thanks to the low profile and tractability of the device.
&#nl
2. Better Understanding of the Science Behind the Sealing
&#nl
"He says that 'it just made logical sense'. We believe it’s currently the only device that does not cause aortic neck dilatation, based on the five-year data and the subsequent rates for reintervention, Type I and no neck expansion," Onopchenko said.
&#nl
3. Appreciation for Endologix in the EVAR Space
&#nl
"He told us that he truly appreciates why we’re the only company that is actively trying to improve the technology in the infrarenal EVAR category," Onopchenko said. "As an academic in an academic medical center, obviously, teaching and evaluating and investigating is central to the mission. We’re the only company that’s doing the kind of market research and indication expansion."
&#nl
So the story serves as an example of how data, education (including simulated deployments), and a positive early-use experience encouraged one physician to expand the use of Ovation fairly quickly, once the benefits of the device became clear to him.
"
  ["description"]=>
  string(5083) "&#nl
It's been a turbulent couple of years for Endologix, but as MD+DI reported in February, the company has been working hard to win back customers.
&#nl
During the company's first-quarter earnings call, CEO John Onopchenko shared a story about a physician at an academic medical center in the Western United States (he did not disclose the name of the physician or the center) who had used Ovation only twice over the course of 2017 and 2018. 
&#nl
Irvine, CA-based Endologix acquired the Ovation platform through its merger with TriVascular in February 2016. It's a low-profile device that has broadened the company's portfolio in terms of patients that can be treated. In June 2017, Endologix reported positive 30-day results from a study evaluating EVAR in women using the Ovation system.
&#nl
"His reasons for not using it more frequently were that there were limited data available and he believed it to be a technically challenging product to deploy," Onopchenko said. "And frankly, he chose as those initial cases, really a challenging reverse-tapered-neck presentation."
&#nl
Late last year, Endologix initiated multiple conversations with this doctor to explain the "why" behind the design of Ovation, along with new evidence in the form of five-year ENCORE data, and those conversations intrigued the doctor enough to spend a day visiting the company's Santa Rosa, CA facility in late January to meet with Onopchenko and other company reps.
&#nl
"He gained a better understanding of the evidence, and he also saw the manufacturing process where Ovation is created first hand," Onopchenko said. "And I’ve got to tell you – I’ve now witnessed this several times – when physicians see how the device is created, it is quite a remarkable experience. Additionally, while we were in Santa Rosa, he completed a successful simulated Ovation device deployment, which is a huge step in uncovering why he initially believed it was technically challenging."
&#nl
Onopchenko said being able to purposefully explain to physicians "the why" behind each step in the process of deploying the endograft goes a long way toward changing how the Ovation device is perceived.
&#nl
"It demystifies and it greatly reduces the initial reaction that our competitors' fuel about it being a technically challenging procedure," Onopchenko said.
&#nl
The visit also allowed that particular physician an opportunity to better identify appropriate Ovation patient selection. The doctor has now treated five patients with Ovation in just the last 60 days, Onopchenko said, and he is now an active site for the company's EVAS2 trial.
&#nl
Here are the reasons the physician gave Endologix for why he has begun to integrate Ovation into his practice since the facility visit.
&#nl
1. The Ability to Treat More Patients on IFU
&#nl
Onopchenko said the doctor is able to treat more patients in accordance with the product label's instructions for use, thanks to the low profile and tractability of the device.
&#nl
2. Better Understanding of the Science Behind the Sealing
&#nl
"He says that 'it just made logical sense'. We believe it’s currently the only device that does not cause aortic neck dilatation, based on the five-year data and the subsequent rates for reintervention, Type I and no neck expansion," Onopchenko said.
&#nl
3. Appreciation for Endologix in the EVAR Space
&#nl
"He told us that he truly appreciates why we’re the only company that is actively trying to improve the technology in the infrarenal EVAR category," Onopchenko said. "As an academic in an academic medical center, obviously, teaching and evaluating and investigating is central to the mission. We’re the only company that’s doing the kind of market research and indication expansion."
&#nl
So the story serves as an example of how data, education (including simulated deployments), and a positive early-use experience encouraged one physician to expand the use of Ovation fairly quickly, once the benefits of the device became clear to him.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(86) "https://www.mddionline.com/how-endologix-renewed-one-doctors-confidence-ovation-device"
  ["blog_url"]=>
  string(86) "https://www.mddionline.com/how-endologix-renewed-one-doctors-confidence-ovation-device"
  [15]=>
  string(19) "2019-05-07 04:14:09"
  ["add_date"]=>
  string(19) "2019-05-07 04:14:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:39"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2082"
  ["article_id"]=>
  string(4) "2082"
  [1]=>
  string(44) "Public dread of nuclear power limits its use"
  ["article_title"]=>
  string(44) "Public dread of nuclear power limits its use"
  [2]=>
  string(150) "Nuclear power has been a part of the American energy portfolio since the 1950s, but for a number of reasons, the general public has long felt a signif"
  ["short_description"]=>
  string(150) "Nuclear power has been a part of the American energy portfolio since the 1950s, but for a number of reasons, the general public has long felt a signif"
  [3]=>
  string(172) "Nuclear power has been a part of the American energy portfolio since the 1950s, but for a number of reasons, the general public has long felt a significant dread about it. "
  ["description"]=>
  string(172) "Nuclear power has been a part of the American energy portfolio since the 1950s, but for a number of reasons, the general public has long felt a significant dread about it. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190506160727.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/05/190506160727.htm"
  [15]=>
  string(19) "2019-05-07 04:07:27"
  ["add_date"]=>
  string(19) "2019-05-07 04:07:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:23"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:23"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1889"
  ["article_id"]=>
  string(4) "1889"
  [1]=>
  string(85) "SGLT2 Inhibitors for Diabetes Linked to Rare 'Flesh-Eating' Genital Infection"
  ["article_title"]=>
  string(85) "SGLT2 Inhibitors for Diabetes Linked to Rare 'Flesh-Eating' Genital Infection"
  [2]=>
  string(150) "MONDAY, May 6, 2019 -- Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease -- but one day you notice pa"
  ["short_description"]=>
  string(150) "MONDAY, May 6, 2019 -- Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease -- but one day you notice pa"
  [3]=>
  string(253) "MONDAY, May 6, 2019 -- Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease -- but one day you notice pain, redness and a foul odor in your genital area.&#nlIf this happens, new research suggests you need..."
  ["description"]=>
  string(253) "MONDAY, May 6, 2019 -- Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease -- but one day you notice pain, redness and a foul odor in your genital area.&#nlIf this happens, new research suggests you need..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(231) "https://www.drugs.com/news/sglt2-inhibitors-diabetes-linked-rare-flesh-eating-genital-infection-82289.html?utm_source=ddc&utm_medium=rss&utm_campaign=SGLT2+Inhibitors+for+Diabetes+Linked+to+Rare+%27Flesh-Eating%27+Genital+Infection"
  ["blog_url"]=>
  string(231) "https://www.drugs.com/news/sglt2-inhibitors-diabetes-linked-rare-flesh-eating-genital-infection-82289.html?utm_source=ddc&utm_medium=rss&utm_campaign=SGLT2+Inhibitors+for+Diabetes+Linked+to+Rare+%27Flesh-Eating%27+Genital+Infection"
  [15]=>
  string(19) "2019-05-07 03:05:59"
  ["add_date"]=>
  string(19) "2019-05-07 03:05:59"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:49"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}